Ixazomib enhances parathyroid hormone–induced β-catenin/T-cell factor signaling by dissociating β-catenin from the parathyroid hormone receptor

Abstract

The anabolic action of PTH in bone is mostly mediated by cAMP/PKA and Wnt-independent activation of β-catenin/T-cell factor (TCF) signaling. β-Catenin switches the PTH receptor (PTHR) signaling from cAMP/PKA to PLC/PKC activation by binding to the PTHR. Ixazomib (Izb) was recently approved as the first orally administered proteasome inhibitor for the… (More)
DOI: 10.1091/mbc.E17-02-0096

Topics

9 Figures and Tables